NCT06845124View on ClinicalTrials.gov

A Trial to Investigate the Effects of Cannabidiol Plus Naltrexone on Alcohol Craving in Patients With Alcohol Dependence

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

July 1, 2025

Primary Completion Date

April 1, 2028

Study Completion Date

September 30, 2028

Conditions
Alcohol AddictionAlcoholism
Interventions
DRUG

Cannabidiol capsules

800mg (trial arm 1) or 1200mg (trial arm 2) Cannabidiol capsules will be administered daily over the course of 14 days.

DRUG

Naltrexone (drug)

All participants will receive 50mg Naltrexone daily as oral tablet throughout the study.

DRUG

Placebo

Placebo capsules matching the cannabidiol capsules will be administered daily.

Trial Locations (2)

68159

Central Institute of Mental Health, Mannheim

69168

Psychiatric Centre North Baden (PZN), Wiesloch

All Listed Sponsors
collaborator

Heidelberg University - Institute of Medical Biometry (IMBI)

UNKNOWN

collaborator

Heidelberg University - Coordination Centre for Clinical Trials (KKS) of Heidelberg University

UNKNOWN

collaborator

German Federal Ministry of Education and Research

OTHER_GOV

lead

Central Institute of Mental Health, Mannheim

OTHER

NCT06845124 - A Trial to Investigate the Effects of Cannabidiol Plus Naltrexone on Alcohol Craving in Patients With Alcohol Dependence | Biotech Hunter | Biotech Hunter